BPC-157

Safety Profile

How It Works

BPC-157 works by boosting the body's natural healing processes through multiple pathways simultaneously. It increases blood vessel growth to injured areas (angiogenesis), relaxes blood vessels by increasing nitric oxide production, helps cells migrate to wound sites faster, and enhances growth hormone signaling in tendons. Rather than acting like a key in one lock, it appears to turn up the volume on several repair systems at once.

Reported Dosing References

10 mg IV infusion on day 1 and 20 mg IV infusion on day 2 in two healthy adults.

Studies

No adequately powered, peer-reviewed randomized human efficacy trial was identified in the page-building corpus.

Legal Status

Not FDA-approved; no FDA-approved BPC-157 drug identified in official/OPSS summary sources. Do not represent BPC-157 as an approved drug, supplement ingredient, or routine clinical therapy. FDA's public bulk-substance page places BPC-157 in the nominated-but-withdrawn section while preserving safety concern language. This supersedes older page language that treated BPC-157 simply as an active Category 2 substance; PepStack should show a dated current-status card. FDA has scheduled July 23, 2026 discussion of BPC-157 free base/BPC-157 acetate for potential inclusion on the 503A Bulks List, with ulcerative colitis listed as the reviewed use. Set an automatic update trigger for PCAC background materials, meeting transcript/minutes, recommendations, and FDA follow-up action. Not FDA-approved; no FDA-approved BPC-157 drug identified in official/OPSS summary sources. Do not represent BPC-157 as an approved drug, supplement ingredient, or routine clinical therapy. FDA's public bulk-substance page places BPC-157 in the nominated-but-withdrawn section while preserving safety concern language. This supersedes older page language that treated BPC-157 simply as an active Category 2 substance; PepStack should show a dated current-status card. FDA has scheduled July 23, 2026 discussion of BPC-157 free base/BPC-157 acetate for potential inclusion on the 503A Bulks List, with ulcerative colitis listed as the reviewed use. Set an automatic update trigger for PCAC background materials, meeting transcript/minutes, recommendations, and FDA follow-up action. Not FDA-approved for any human therapeutic indication. FDA Category 2 bulk drug substance -- identified as presenting significant safety risks, not eligible for routine compounding under Section 503A. Not DEA-scheduled. Available as a research chemical. Official FDA publication pending as of March 2026.